Valuation and Earnings This table compares NexImmune and Evotec"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NexImmune N/A N/A -$32.34 million ($18.29) N/A Evotec $572.16 million 1.71 $7.14 million $0.41 7.24 Evotec has higher revenue and earnings than NexImmune. NexImmune is trading at a

Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A NexImmune N/A -534.32% -213.72% Institutional and Insider Ownership 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned

NexImmune (NASDAQ: NEXI ) stock is no longer trading on the Nasdaq Exchange after the company's shares were delisted on Friday morning. This saw shares of NEXI stock removed from the Nasdaq Exchange when markets opened this morning.

Embattled biotechnology firm NexImmune (NASDAQ: NEXI ) is seeing shares skyrocket on Thursday, possibly due to anticipation around a lingering business matter. Due to severe financial struggles, management has sought to dissolve the enterprise.

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6.

Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum.

Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021.

Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.